SKP2 and chronic myelogenous leukemia, BCR-ABL1 positive: Importantly, the results obtained from the present study revealed that the expression levels of SKP2 were significantly higher in the CML patients with warning/failure responses to IM treatment compared to the CML patients with optimal responses at the early response stage.